AbbVie (ABBV) Share-based Compensation Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Stock Comp. Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
7.06% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-0.66% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
12.36% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
8.46% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
16.86% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
9.73% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
37.34% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
6.17% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
12.36% |
| Dec 31, 2025 |
5.95% |
| Sep 30, 2025 |
18.37% |
| Jun 30, 2025 |
18.71% |
| Mar 31, 2025 |
10.24% |
| Dec 31, 2024 |
8.33% |
| Sep 30, 2024 |
10.27% |
| Jun 30, 2024 |
11.09% |
| Mar 31, 2024 |
8.96% |
| Dec 31, 2023 |
-2.77% |
| Sep 30, 2023 |
-7.07% |
| Jun 30, 2023 |
-8.80% |
| Mar 31, 2023 |
12.64% |
| Dec 31, 2022 |
18.66% |
| Sep 30, 2022 |
18.88% |
| Jun 30, 2022 |
7.14% |
| Mar 31, 2022 |
17.42% |
| Dec 31, 2021 |
22.60% |
| Sep 30, 2021 |
21.64% |
| Jun 30, 2021 |
23.21% |
| Mar 31, 2021 |
12.09% |
| Dec 31, 2020 |
20.88% |
| Sep 30, 2020 |
31.65% |
| Jun 30, 2020 |
45.89% |
| Mar 31, 2020 |
15.81% |
| Dec 31, 2019 |
1.75% |
| Sep 30, 2019 |
2.82% |
| Jun 30, 2019 |
-14.05% |
| Mar 31, 2019 |
11.05% |
| Dec 31, 2018 |
9.72% |
| Sep 30, 2018 |
10.89% |
| Jun 30, 2018 |
15.62% |
| Mar 31, 2018 |
17.08% |
| Dec 31, 2017 |
21.43% |
| Sep 30, 2017 |
17.29% |
| Jun 30, 2017 |
15.75% |
| Mar 31, 2017 |
9.98% |
| Dec 31, 2016 |
26.56% |
| Sep 30, 2016 |
18.95% |
| Jun 30, 2016 |
43.88% |
| Mar 31, 2016 |
16.62% |
| Dec 31, 2015 |
19.57% |
| Sep 30, 2015 |
22.39% |
| Jun 30, 2015 |
16.26% |
| Mar 31, 2015 |
9.35% |